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AbstrACt
Objectives Acute rhinosinusitis (ARS) has a high 
incidence. Diagnosis is clinical, and evolution is mostly 
self-limited. The aim of this study was to describe the 
sociodemographic characteristics and use of diagnostic 
tools and medications in patients with ARS.
Design This is a prospective observational study in real-
life clinical practice.
setting Patients with clinical diagnosis of ARS (n=2610) 
were included from ear, nose and throat clinics in Spain. A 
second visit at resolution was done.
Participants Patients were classified according to the 
duration of symptoms: viral ARS (≤10 days), postviral 
ARS (>10 days, ≤12 weeks) and chronic rhinosinusitis 
(>12 weeks).
Main outcome measures Sociodemographic 
characteristics, symptoms, disease severity, quality of life 
(Sino-Nasal Outcome Test-16), used diagnostic tools and 
medications, and the management performed by primary 
care physicians (PCPs) and by otorhinolaryngologists 
(ORLs) were assessed.
results Of the patients 36% were classified as having 
viral ARS, 63% postviral ARS and 1% as chronic 
rhinosinusitis. Working in a poorly air-conditioned 
environment was a risk factor (OR: 2.26, 95% CI 1.27 
to 4.04) in developing postviral ARS. A higher number 
of diagnostic tools (rhinoscopy/endoscopy: 80% vs 
70%; plain X-ray: 70% vs 55%; CT scan: 22% vs 
12%; P<0.0001) were performed in postviral than 
viral cases. PCPs performed more X-rays than ORLs 
(P<0.0001). Patients, more those with postviral than 
viral ARS, received a high number of medications (oral 
antibiotics: 76% vs 62%; intranasal corticosteroids: 54% 
vs 38%; antihistamines: 46% vs 31%; mucolytic: 48% 
vs 60%; P<0.0001). PCPs prescribed more antibiotics, 
antihistamines and mucolytics than ORLs (P<0.0068). 
More patients with postviral than viral ARS reported 
symptoms of potential complications (1.5% vs 0.4%; 
P=0.0603). Independently of prescribed medications, 
quality of life was more affected in patients with postviral 
(38.7±14.2 vs 36.0±15.3; P=0.0031) than those with viral 
ARS. ARS resolution was obtained after 6.04 (viral) and 
16.55 (postviral) days, with intranasal corticosteroids being 
associated with longer (OR: 1.07, 95% 1.02 to 1.12) and 
phytotherapy with shorter (OR: 0.95, 95% CI 0.91 to 1.00) 
duration.
Conclusions There is a significant overuse of diagnostic 
tools and prescribed medications, predominantly oral 
antibiotics, by PCPs and ORLs, for viral and postviral  
ARS.
IntrODuCtIOn
Rhinosinusitis is an inflammatory process 
of the paranasal sinuses with high preva-
lence in clinical practice1 and a significant 
impact on quality of life (QoL).2 3 Acute 
rhinosinusitis (ARS) is mainly an inflamma-
tory disease, usually caused by a viral infec-
tion, although other processes such allergic 
rhinitis, anatomical abnormalities, nasal 
polyps, tobacco smoke or nasal decongestant 
abuse can constitute predisposing factors.1 
Viral ARS (common cold) is usually self-re-
solved and accounts for most of ARS cases.4 
Postviral ARS occurs as a perpetuation of the 
inflammatory condition, even when the viral 
agent has gone.5 Only a small percentage of 
the latter (0.5%–2%) actually leads to acute 
strengths and limitations of this study
 ► This is a real-life prospective study that provides 
physicians’  real approach  to the management of 
acute rhinosinusitis in their daily practice in Spain.
 ► The high number of patients included in the study 
makes the results highly extensible to the general 
population.
 ► Following the  European Position Paper on 
Rhinosinusitis and Nasal Polyps classification 
criteria makes this study adequate for international 
guidelines.
 ► The study population cannot be considered a random 
sample, so the results have been interpreted in 
terms of association, avoiding any interpretation in 
terms of causality.
 ► The management performed by primary care 
physicians and otorhinolaryngologists cannot 
directly be compared as they treat the same patients 
but in different time of disease.
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bacterial rhinosinusitis.6 7 The incidence of ARS is very 
high, with adults having between two and five common 
cold episodes per year,8 while the incidence of postviral 
ARS has been reported to be 3.4 cases per 100 inhabi-
tants/year.9 Orbital, osseous or intracranial complica-
tions may occur, but their incidence is very low (about 
three cases per million people).10 
The diagnosis of ARS is based on the clinical history of a 
sudden onset of nasal symptoms (nasal congestion/obstruc-
tion/blockage, rhinorrhoea/postnasal drip, facial pain/
pressure, and/or reduction/loss of smell) supported by 
physical examination.1 Microbiological or imaging studies 
are not required,11 12 with imaging being indicated when 
symptoms that suggest complications appear.1
The goals of ARS treatment are to provide symptom-
atic relief, accelerate time of remission and prevent 
complications. Although antibiotics have traditionally 
been the treatment most often indicated for ARS, there is 
no evidence that antibiotics are significantly better than 
placebo in viral (common cold) and postviral ARS.13 In 
fact, a number of bacterial ARS cases have been resolved 
without antibiotics at all.14 15 Furthermore, the use of anti-
biotics does not prevent complications.10 Indeed, their 
overuse can lead to a number of side effects and to an 
increase of antibiotic resistance.16 In the last two decades 
several studies have demonstrated that the addition of 
intranasal corticosteroids (INS) to antibiotics, or even 
INS in monotherapy, may provide an excellent option to 
treat postviral ARS.17 18 Accordingly, the European Posi-
tion Paper on Rhinosinusitis and Nasal Polyps (EPOS) 
2012 recommended symptomatic relievers (analgesics, 
saline serum and decongestants) for viral/common cold 
cases, INS for postviral cases, and the addition of oral 
antibiotic for bacterial/complicated cases or well-estab-
lished complications.19 20 Recent studies have shown that 
selected herbal medicines (phytotherapy) may consti-
tute an additional medical option to treat viral/postviral 
ARS.21–24 However, a number of very commonly used 
medications such as mucolytics, antihistamines, probi-
otics or vitamin C have not shown any evidence of efficacy 
in ARS.1
The objectives of the PROSINUS study (PROspective epide-
miological study about the diagnosis and therapeutic management 
of Acute RhinoSINUsitis in otorhinolaryngology clinics in Spain) 
were (1) to describe and compare the diagnostic tools and 
therapeutic medications used by primary care physicians 
(PCPs) and otorhinolaryngologists (ORLs) to manage 
viral or postviral ARS in Spain; (2) to assess the risk factors 
leading to postviral ARS; and (3) to assess the evidence 
of the efficacy of those medications most often used to 
decrease disease duration and prevent complications in 
patients with viral or postviral ARS.
MethODOlOgy
study design, participants and setting
The PROSINUS study was a prospective, real-life and 
descriptive study that analysed a cohort of patients 
(n=2610) with acute ARS in Spain. Patients were recruited 
by ORLs (n=284) throughout Spain and classified as 
suffering from viral (common cold) or postviral ARS 
based on the EPOS criteria. Each ORL represented 
9.2±1.8 patients (range 1–11).
To define and classify rhinosinusitis, we used the defi-
nitions provided by the EPOS consensus.25 ARS was clini-
cally defined by a sudden onset of two or more symptoms, 
one of which should be either nasal blockage/obstruc-
tion/congestion or anterior/posterior nasal discharge. 
Additional symptoms could be facial pain/pressure and/
or reduction/loss of smell. Three different phenotypes of 
ARS were defined. Viral ARS (common cold) was defined 
as the presence of symptoms of rhinosinusitis for less than 
10 days, postviral ARS was defined as symptoms lasting 
for >10 days and <12 weeks, and chronicity when symp-
toms lasted for ≥12 weeks.
Inclusion criteria
Patients of both gender, ≥18 years old, and those who 
come to see the ORL with symptoms consistent with the 
clinical diagnosis of viral/postviral ARS according to the 
EPOS criteria were included in the study.25
Exclusion criteria
Patients with exacerbations of diagnosed chronic rhinosi-
nusitis (CRS), with clinical suspicion of bacterial ARS 
(severe cases with fever >38°C or unilateral severe pain), 
or patients not able to do follow-up visits or with a high 
risk of dropout were excluded.
Study visits
Patients were included between January 2007 and March 
2008. Visit 1 was done at inclusion, while visit 2 was done 
after 2–4 weeks of inclusion. Where patients still had 
symptoms at visit 2, visit 3 was performed after 12 weeks 
of inclusion.
Patients’ involvement
Participants were involved in the study on the basis of 
daily clinical practice. Patients did not participate in the 
design of the study.
Ethics
All patients signed the informed consent.
Measurements and outcomes
At visit 1, the sociodemographic and anthropometric 
characteristics, duration of symptoms (days), severity of 
disease, QoL (Sino-Nasal Outcome Test-16 (SNOT-16)), 
diagnostic tools used, and medications prescribed before 
inclusion by PCPs were recorded. The general health 
status prior to and during the disease was also recorded. 
At visit 2, the duration of episode (number of days), symp-
toms addressing potential complications, diagnostic tools 
used and medications prescribed between visits 1 and 2 
by ORLs, severity of disease, and QoL (SNOT-16) were 
also recorded. Where visit 3 was required (based on no 
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resolution at visit 2), the time of disease resolution or 
chronification was recorded.
Demographic characteristics
At visit 1 the following characteristics were recorded: 
age (years), gender, area of residence (rural, <2000 
inhabitants; semirural, 2000–10 000 inhabitants; and 
urban, >10 000 inhabitants), education level (no educa-
tion or unfinished, primary or secondary education, and 
higher education or college), workplace environment 
(proper air-conditioned, poorly air-conditioned, outdoor 
work, unemployed), social and family circumstances 
(living as part of a family or in a partnership, single, 
living in an institution or residence, or living in shared 
housing), and home environment (well air-conditioned, 
airy).
Use of diagnostic tools
We recorded the use of anterior rhinoscopy or nasal 
endoscopy (to assess oedema, congestion or mucopuru-
lent secretion from the middle meatus), imaging tech-
niques (X-ray, CT scan) and microbiological cultures 
(culture of nasal secretions). This information was 
recorded at visits 1 and 2 in order to know the tests 
performed before (by PCPs) and after (by ORLs) the 
inclusion in the study.
Prescription of medications
Prescribed medications, either recommended (antibi-
otics, INS, nasal saline irrigation, nasal decongestants, 
phytotherapy) or non-recommended (antibiotics, antihis-
tamines, mucolytics) by the EPOS consensus to treat ARS, 
were recorded at visits 1 and 2.
Figure 1 Flow chart of participants in the PROSINUS study (PROspective epidemiological study about the diagnosis and 
therapeutic management of Acute RhinoSINUsitis in otorhinolaryngology clinics in Spain). Two phenotypes for ARS and one 
for CRS were analysed: patients with viral ARS/common cold (36%), postviral ARS (63%) and CRS (1%). VAS, visual analogue 
scale. a% refers to patients selected at visit 1 (n=1678); b% refers to patients considered valid at visit 2 (n=1362). ARS, 
acute rhinosinusitis; CRS, chronic rhinosinusitis; EPOS, European Position Paper on Rhinosinusitis and Nasal Polyps; RS, 
rhinosinusitis; VAS, visual analogue scale. 
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Episode duration and disease severity
Duration of symptoms (days) was recorded at visits 1 and 
2, and at visit 3 when needed. Severity was assessed at 
visits 1 and 2 using a visual analogue scale (VAS, 0–10 cm)1 
after answering the question ‘how troublesome are your symp-
toms of rhinosinusitis?’ (0, not troublesome, to 10, worst 
imaginable). Disease severity was assessed using a VAS 
(0–10 cm) and classified as mild (VAS 0–3 cm), moderate 
(VAS >3–7 cm) or severe (VAS >7–10 cm).1 26
QoL and health status
The SNOT-16 questionnaire was used to assess the impact 
of disease and its treatment on the QoL at both visits 1 and 
2. Each of the 16 items was scored from 0 (not affected) 
to 5 (extremely affected). The overall score runs from 
0 (better QoL) to 80 (worst QoL). The general health 
status prior to and during the disease was recorded using 
a VAS (0–10 cm).
Disease complications
Instead of recording the presence of complications, 
the study recorded the presence of symptoms linked to 
complications, as stated by the EPOS guidelines.25 Orbital 
symptoms (palpebral oedema, orbital pain, diplopia, 
exophthalmos, decrease in visual acuity), neurological 
symptoms (meningeal symptoms, neurological deficit) 
and frontal symptoms (frontal oedema, severe frontal 
pain) were assessed. In addition, other sinonasal signs 
and symptoms of a potentially different disease involved 
were also recorded (unilateral symptoms, bleeding, 
crusts, lacrimation and conjunctiva hyperaemia, or 
cacosmia).
Table 1 Sociodemographic characteristics of acute rhinosinusitis (ARS) study population
Demographic characteristics Viral ARS (n=494) Postviral ARS (n=857) Total ARS (n=1351) P value
Age* 42.2±14.3 (424) 42.6±14.0 (761) 42.4±14.1 (1185) 0.6871†
 Gender‡ 
  Men 234/471 (50) 375/821 (46) 609/1292 (47) 0.1651§
Area of  residence‡ 
  Rural 23 (5) 52 (6) 75 (6) 0.1094§ 
  Semirural 52 (11) 120 (15) 172 (13)
  Urban 392 (84) 653 (79) 1045 (81)
  Total 467 (100) 825 (100) 1292 (100)
Place of residence‡ 
  With family/couple 440 (89) 748 (88) 1188 (88) 0.4976¶
  Single 44 (9) 91 (11) 135 (10)
  Institution/residence 4 (1) 3 (0) 7 (1)
  Shared housing 6 (1) 11 (1) 17 (1)
  Total 494 (100) 853 (100) 1347 (100)
Education level‡ 
  No/unfinished education 45 (9) 84 (10) 129 (10) 0.2855§
  Primary/secondary education 219 (45) 415 (49) 634 (47)
  College/higher education 225 (46) 355 (42) 580 (43)
  Total 489 (100) 854 (100) 1343 (100)
Daily activity‡ 
  Well air-conditioned enclosure 332 (68) 534 (63) 866 (65) 0.0092§
  Poorly air-conditioned enclosure 37 (8) 113 (13) 150 (11)
  Outdoors 38 (8) 54 (6) 92 (7)
  Unemployed 78 (16) 146 (17) 224 (17)
  Total 485 (100) 847 (100) 1332 (100)
 Well air-conditioned home‡ 449/477 (94) 751/823 (91) 1200/1300 (92) 0.0605§
Airy home‡ 395/415 (95) 731/757 (97) 1126/1172 (96) 0.2430§ 
*Arithmetic mean±SD (n).
†Student’s t-test.
‡n (%).
§χ2 test.
¶Fisher's exact test.
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Data management and statistical analysis
Study size
This was an observational study without a specific hypoth-
esis as the main objective. Therefore, the sample size was 
determined by logistical and cost reasons rather than by 
analytical criteria.
The sociodemographic characteristics, nasal symptoms, 
use of diagnostic tools, prescribed medications, disease 
severity and QoL were compared between patients with 
viral (common cold) and postviral ARS. Differences in 
quantitative measures were evaluated by Student’s t-test 
for independent groups, and differences in qualitative 
measures were assessed with the χ2 or Fisher’s exact test as 
appropriate. The improvement in patient’s QoL (SNOT-
16) between visits 1 and 2 was evaluated by Student’s t-test 
for paired groups.
Logistic regression models were estimated to assess the 
associations with postviral ARS using viral ARS as the refer-
ence group. The relationships between treatments (medi-
cation) and disease duration, QoL at visit 2 and the risk of 
complications were also assessed. These associations were 
evaluated by linear regression using the duration and the 
total score of SNOT-16 in logarithmic scale, and by logistic 
regression for the complications assessment. Multivariate 
regression models were estimated by a backward selection 
procedure using 0.05 as significance level for removal 
from the model. All regression models were adjusted for 
the study group (viral and postviral ARS). Additionally, 
regression models to evaluate associations between medi-
cation and duration, or medication and complications, 
were also adjusted for severity at recruitment, whereas 
models to evaluate associations between medication and 
QoL at visit 2 were adjusted for QoL at visit 1. Interactions 
between treatments were also assessed. Statistical analysis 
was performed using Stata V.14.
results
Demographic characteristics
From the initial 1678 patients included at visit 1, 1499 
(89%) completed visit 2, with 1362 patients being consid-
ered valid for the study (figure 1). Patients were classified 
into three groups according to the duration of symptoms 
of rhinosinusitis: 36% (n=494) had viral ARS (common 
cold) with a mean duration of 6.0 days (95% CI 5.9 to 
6.2), 63% (n=857) had postviral ARS with a mean dura-
tion of 16.5 days (95% CI 15.8 to 17.3), and 1% (n=11) 
Table 2 Frequency of symptoms in viral/postviral acute 
rhinosinusitis (ARS)
Viral ARS
(n=494)
Postviral ARS
(n=857) P value
Total, N (%) 494 (100) 857 (100)
Nasal 
obstruction*
481/493 (98) 829/857 (97) 0.3847†
Rhinorrhoea* 464/490 (95) 800/854 (94) 0.4482†
Facial pressure/
pain*
370/485 (76) 653/848 (77) 0.7659†
Loss of smell* 275/470 (59) 533/847 (63) 0.1148†
*Number of cases and proportion within group (%).
†χ2 test.
Figure 2 Frequency of symptoms in patients with acute rhinosinusitis (ARS). Bars represent the frequency (%) of individual 
sinonasal symptoms in each level of severity for both viral and postviral ARS. Reported frequency of symptoms was always 
higher in the highest severity level. *P<0.05; NS, not significant.
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had chronic symptoms (CRS). Patients with CRS were 
excluded from this analysis, and therefore the sample size 
for analysis was 1351 patients (36% with viral and 63% 
with postviral ARS). By definition, all patients with viral 
ARS were cured before 10 days. From those with postviral 
ARS, 74.3% of episodes were resolved before visit 2, and 
25.7% in the time between visits 2 and 3 (figure 1).
More women (53%) than men participated in the study, 
with a similar ratio applying to both viral and postviral 
ARS sample groups. Both groups were also homogeneous 
with regard to weight, height or ethnicity. Most patients 
(81%) lived in an urban environment, with no differ-
ences between disease groups (table 1). With regard to 
workplace, most patients with either viral (68%) or post-
viral (63%) ARS worked in a well air-conditioned envi-
ronment. Patients working in a poorly air-conditioned 
environment were significantly higher in postviral (13%) 
than viral (8%) ARS (P=0.0092). Half of the patients 
(46%) reported a history of ARS episodes, without differ-
ences between groups.
nasal symptoms
Nasal congestion/obstruction/blockage (98%) and 
anterior/posterior nasal discharge (95%) were the most 
frequent symptoms of ARS, followed by facial pressure/
pain (77%) and reduction/loss of smell (60%). No differ-
ences were found between patients with viral and postviral 
ARS (table 2). By excluding nasal discharge in the post-
viral ARS group, the frequency of symptoms was however 
significantly higher (P<0.05) when disease severity 
increased, and this was more relevant for hyposmia and 
facial pressure/pain in postviral ARS (figure 2).
Disease severity
Severity by VAS for postviral ARS was slightly higher 
(7.13±1.48 cm) than for viral ARS (6.98±1.60 cm), although 
this was not statistically significant. The general health 
status (VAS) during the disease episode was also similar in 
viral (5.45±1.89 cm) and in postviral (5.59±1.89 cm) ARS, 
but significantly affected when compared with the general 
health status they had retrospectively, before the episode 
(8.85±1.40 cm and 8.67±1.76 cm, respectively).
When comparing viral and postviral ARS, all three 
levels of severity were similar (mild: 2.65±0.57 cm vs 
2.72±0.57 cm; moderate: 6.11±0.97 cm vs 6.09±1.00 cm; 
and severe: 8.36±0.60 vs 8.35±0.64). In addition, no 
differences were found between viral and postviral ARS 
in general health status (VAS) in the three severity levels, 
either before (retrospective) or during the disease.
Qol (snOt-16)
At visit 1, the SNOT-16 global score was worse in postviral 
(38.7±14.2; P=0.0031) than in viral ARS (36.0±15.3). In 
addition, a higher SNOT-16 score was strongly related to 
a higher disease severity degree in both viral and post-
viral ARS (P<0.0001). At visit 2, the SNOT-16 global score 
significantly improved compared with visit 1 for both 
postviral (15.9±15.9; P<0.0001) and viral (14.1±17.2; 
Figure 3 Quality of life (SNOT-16) in patients with ARS. Changes in the individual values (solid lines) and in the average values 
of each group (dashed lines). At baseline, SNOT-16 score was more affected (*P<0.05) in postviral than in viral ARS. SNOT-16 
score significantly improved (‡P<0.05) after disease resolution, with no differences between both ARS phenotypes. ARS, acute 
rhinosinusitis; SNOT-16, Sino-Nasal Outcome Test 16.
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P<0.0001) ARS. No significant differences (P=0.0726) 
between viral and postviral groups were found for the 
SNOT-16 score (figure 3).
Diagnostic tools
Overall, including all tests conducted before and after 
patients were recruited for the study, the diagnostic tools 
most frequently performed were anterior rhinoscopy/
nasal endoscopy (76%), X-ray (64%), CT scan (18%) 
and microbiology cultures (7%), with all of them being 
more frequent (P<0.0002) in postviral than in viral ARS 
(figure 4). PCPs performed more X-ray (45% vs 36%; 
P<0.0001) than ORLs, who performed more rhinoscopy/
endoscopy (68% vs 27%; P<0.0001), CT scans (15% vs 
5%; P<0.0001) and microbiology cultures (5% vs 2%; 
P<0.0001). With regard to disease severity, the perfor-
mance of X-ray increased with higher levels of severity 
in postviral (P=0.0045) but not in viral (P=0.0606) ARS. 
In contrast, the performance of CT scan increased with 
higher severity levels in viral (P=0.0024) but not in post-
viral ARS (P=0.2631).
Medications
In viral and postviral ARS, the most frequently prescribed 
medications were oral antibiotic (62% vs 76%), topical 
steroids (38% vs 54%), antihistamines (31% vs 46%), nasal 
decongestants (38% vs 48%), mucolytics (48% vs 60%), 
nasal saline (40% vs 54%) and nasal phytotherapy (41% vs 
46%). All drugs were more frequently prescribed in patients 
with postviral than with viral ARS (P<0.0006 for all compar-
isons), except for nasal phytotherapy (P=0.1413) (figure 5).
There were only a few patients (3%) who did not 
receive any treatment, while most of the patients with ARS 
received more than one medication. Based on the EPOS 
recommendations, oral antibiotics were incorrectly 
prescribed in 62% of patients with viral ARS (common 
cold), while only 54% of patients with postviral ARS were 
treated with INS (table 3).
In addition, PCPs prescribed more oral antibiotics 
(53% vs 39%; P<0.0001), antihistamines (26% vs 22%; 
P=0.0068), nasal decongestants (34% vs 18%; P<0.0001), 
mucolytics (45% vs 21%; P<0.0001) and intranasal 
saline (34% vs 25%; P<0.0001) than ORLs. However, 
ORLs prescribed more nasal phytotherapy (39% vs 9%; 
P<0.0001) and showed a tendency to prescribe more INS 
(30% vs 26%; P=0.0721) than PCPs (figure 5).
With regard to disease severity, antibiotics and mucol-
ytics were more frequently prescribed in severe cases of 
both viral and postviral ARS (P<0.0225 for all compari-
sons), while antihistamines were more prescribed in 
severe viral ARS (P=0.0040), and nasal decongestants 
(P=0.0408) in severe postviral ARS.
No significant association was found between medica-
tion and QoL (SNOT-16 score) or the risk of complica-
tions at visit 2. Interactions between treatments were also 
assessed, although none of them showed a statistically 
significant difference.
Figure 4 Diagnostic tools performed in patients with acute rhinosinusitis. Percentage of patients undergoing different 
diagnostic tools, for both viral and postviral acute rhinosinusitis, recommended by either primary care physicians or 
otorhinolaryngologists. *P<0.05; NS, not significant.
group.bmj.com on February 28, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Jaume F, et al. BMJ Open 2018;8:e018788. doi:10.1136/bmjopen-2017-018788
Open Access 
Disease complications
More patients with postviral (1.5%) than viral ARS (0.4%) 
had signs or reported symptoms potentially linked to 
rhinosinusitis complications, such us ophthalmic, neuro-
logical or frontal (P=0.0603) complications. In addition, 
there were patients who reported other unusual signs 
and symptoms (5.6% in postviral and 3% in viral ARS) 
that could potentially be linked to a different diagnosis 
(table 4). No differences were found when comparing the 
degree of disease severity.
Factors associated with disease duration
All population characteristics were analysed to iden-
tify factors associated with postviral ARS development. 
Table 5 shows the crude estimates for ORs using viral 
ARS as a reference group. In the multivariate analysis we 
found that working in a poorly air-conditioned enclosure 
was the only factor significantly associated with devel-
oping postviral ARS (OR: 2.26, 95% CI 1.27 to 4.04).
The analysis of associations between medication and 
duration, adjusted for type of ARS (viral/postviral) and 
severity at baseline, showed a longer duration of the 
episode in patients who took nasal decongestants, saline 
solutions, antibiotics or INS than in those who did not. 
According to multivariate analysis, phytotherapy (mainly 
Cyclamen europaeum, CE) was related to shorter duration 
(OR: 0.95, 95% CI 0.91 to 1.00, P=0.0480), while INS was 
related to longer duration (OR: 1.07, 95% CI 1.02 to 1.12, 
P=0.0048).
DIsCussIOn
The following were the most significant findings of the 
PROSINUS study: (1) ARS is mostly a self-limited disease, 
with only 1% of chronification; (2) working in a poorly 
air-conditioned environment was a risk factor for common 
cold to develop into postviral ARS; (3) both PCPs and 
ORLs performed a high number of non-indicated diag-
nostic tools, mainly plain X-ray; (4) ORLs and especially 
PCPs prescribed a large number of non-recommended 
medications, with antibiotics being the most significant, 
followed by mucolytics and antihistamines; (5) INS was 
less frequently prescribed by ORLs and even less so by 
PCPs; and (6) there was an association between prescribed 
INS and a longer duration of ARS, and prescribed phyto-
therapy (CE) and shorter episodes of disease.
In the present study only 1% of chronification was found, 
suggesting that most ARS cases tend to be cured inde-
pendently of the prescribed treatment. Spontaneous cure 
with no treatment has been identified in 80% of patients with 
ARS.27 Working in a poorly air-conditioned environment was 
the only identified risk factor (OR: 2.26) in developing post-
viral ARS. Previous studies have suggested the importance of 
other factors such as contact with people with upper respira-
tory complaints,28 winter months (January to March) having 
a risk factor (OR: 2.9) to develop ARS compared with July 
to September,29 allergic rhinitis developing in postviral ARS 
(OR: 4.4) compared with healthy controls,30 and active31 and 
passive32 smoking. In our study the most prevalent symptoms, 
Figure 5 Prescribed medications in patients with acute rhinosinusitis (ARS). Percentage of patients being treated with different 
medications, for both viral and postviral ARS, prescribed by either primary care physicians or otorhinolaryngologists. *P<0.05; 
NS, not significant.
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in both common cold and postviral ARS, were nasal conges-
tion (98%) and discharge (95%), followed by facial pressure/
pain (77%) and smell loss (60%). Although the presence of 
nasal symptoms was biased by inclusion criteria, facial pres-
sure/pain and smell loss were highly associated with severe 
ARS. In a French study done by PCPs, similar findings were 
reported in patients with acute maxillary sinusitis.2 Despite 
the EPOS guidelines1 stating that the diagnosis of ARS is 
mainly clinical (based on symptoms) and supported by nasal 
examination (anterior rhinoscopy or nasal endoscopy), in 
our study, many ORLs and especially PCPs did not perform 
nasal examination (68% and 27%, respectively) in patients 
with ARS. Plain X-ray has proven to have poor sensitivity and 
specificity33 34 and is not recommended in the diagnosis of 
ARS.35 Since Gwaltney et al36 reported that CT scans show 
sinus opacity in most patients (87%) with common cold, this 
imaging technique is only recommended in complicated 
cases.11 The present study shows however that physicians 
from Spain performed a high number of plain X-ray and CT 
scan in postviral ARS (70% and 22%, respectively) but also 
in common cold (55% and 12%, respectively), with plain 
X-ray predominantly being carried out by PCPs, and CT 
scan by ORLs. These practices were not related to suspected 
complications since the frequency of symptoms suggesting 
complications was very low (0.4% in common cold and 1.5% 
in postviral ARS).
Although VAS has been validated to assess CRS severity,1 25 26 
our study has been the first to use it to assess ARS severity. 
Interestingly, VAS score was similar in both viral and postviral 
ARS, suggesting that disease severity is not associated with 
the duration of disease. Patients with severe ARS have more 
smell loss, more facial pain and more impact on QoL than 
patients with moderate and mild ARS. Moreover, plain X-ray 
was more often indicated and antibiotics more generally 
Table 3 Frequency of recommended combined medications in ARS
Recommended medications Viral ARS (n=494) Postviral ARS (n=857) Total ARS (n=1351) Postviral ARS (n=857)
No treatment* 27 (5) 20 (2) 47 (3) 0.0025†
Antibiotic*
  AB (total) 308 (62) 648 (76) 956 (71) <0.0001†
  AB alone 13 (3) 6 (1) 19 (1) 0.0037†
  AB in combination
  (except with CS)
137 (28) 261 (30) 398 (29) 0.2905†
Intranasal CS*
  Topical CS (total) 188 (38) 463 (54) 651 (48) <0.0001†
  Topical CS alone 1 (0) 1 (0) 2 (0) 1.0000‡
  Topical CS in combination 
(except with Ab)
29 (6) 81 (9) 110 (8) 0.0204†
Phytotherapy* 
  Phytotherapy (total) 205 (41) 391 (46) 596 (44) 0.1413†
  Phytotherapy alone 20 (4) 9 (1) 29 (2) 0.0002†
  Phytotherapy in combination 
(except with AB or CS)
39 (8) 46 (5) 85 (6) 0.0654†
Antibiotic + intranasal  CS* 
  AB+topical CS alone 12 (2) 4 (0) 16 (1) 0.0013†
  AB+topical CS in combination 146 (30) 377 (44) 523 (39) <0.0001†
Saline solutions * 
  Saline solutions (total) 197 (40) 462 (54) 659 (49) <0.0001†
  Saline solutions alone 9 (2) 4 (0) 13 (1) 0.0193‡
  Saline solutions in combination 188 (38) 458 (53) 646 (48) <0.0001†
Other combinations without AB, 
intranasal CS or phytotherapy*
70 (14) 52 (6) 122 (9) <0.0001†
Mucolytics* 235 (48) 515 (60) 750 (56) <0.0001†
Antihistamines* 154 (31) 396 (46) 550 (41) <0.0001†
Nasal decongestants* 190 (38) 412 (48) 602 (45) 0.0006†
*Number of cases and proportion within group (%).
†χ2 test.
‡Fisher’s exact test.
AB, antibiotic; ARS, acute rhinosinusitis; CS, corticosteroids.
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prescribed in patients with severe ARS. On the other hand, 
the presence of symptoms linked to complications was not 
different between severity groups. Previous studies have 
reported the impact of ARS on QoL and its improvement 
with INS37 or antibiotics14 using SNOT-20 and SNOT-16, 
respectively. In our study, postviral ARS had a higher impact 
on QoL than common cold but, in both groups, QoL 
improved and reached normal values no matter the treat-
ment used for 2–4 weeks.
Although guidelines suggest that a diagnosis of bacte-
rial ARS should be considered in patients with fever, 
severe unilateral pain, purulent rhinorrhoea and double 
sickening,38 there are real difficulties to differentiate 
between postviral and bacterial ARS. Several studies have 
reported an overuse of antibiotic prescriptions by PCPs. 
Dutch PCPs prescribed antibiotics in 34% of patients with 
moderate ARS,39 while US PCPs did so in 82.3% of ARS 
cases.40 In addition, ARS was behind 3.9% of all diagnoses 
with antibiotic prescription performed by PCPs.41 In our 
study, Spanish physicians prescribed antibiotics in most 
of the ARS cases either in common cold (62%) or in 
postviral ARS (76%). However, PCPs and ORLs overused 
the antibiotic prescription (53% and 39%, respectively). 
A potential explanation for this could be that PCPs may 
consider the term ‘sinusitis’ as a synonym of bacterial 
ARS, instead of being considered as an inflammatory 
condition.42
Current guidelines1 37 and recent systematic reviews20 43 
recommend the use of oral antibiotics in combination with 
INS only in severe bacterial ARS or in complications, yet 
there are no indications for cases of mild to moderate 
non-complicated ARS. The potential benefit of antibiotics 
in treating ARS should be contrasted with the potential of 
inducing antibiotic resistance and the very low incidence 
of serious complications.19 20 Many recent studies have 
addressed the high costs of antibiotic resistance.41 de Kraker 
et al44 calculated the cost related to Staphylococcus aureus 
and Escherichia coli infections and their antibiotic resistance 
in Europe resulting in 8000 deaths and €62 million for 
2007. Surprisingly, the incidence of infections by resistant 
bacteria was higher in countries with high use (ie, Portugal) 
compared with those with lower use (ie, Iceland or Norway) 
of antibiotics. Similarly, Carter et al45 calculated the cost of 
infections produced by pandrug-resistant Gram-negative 
bacteria in the UK in an estimated 79 000 deaths over a 
20-year period. With regard to the role of antibiotics on 
preventing complications, Babar-Craig et al46 reported 
that complications requiring surgical intervention were 
Table 4 Frequency of unusual symptoms and symptoms suggesting a complication of acute rhinosinusitis (ARS)
Total ARS
(n=1351)
Viral ARS
(n=494)
Postviral ARS
(n=857) P value
Unusual symptoms 
(consider different 
diagnosis)*
Total 49 (3.6) 12 (2.4) 37 (4.3) 0.0738†
Unilateral symptoms 8 (0.6) 2 (0.4) 6 (0.7) 0.7179
Bleeding 30 (2.2) 8 (1.6) 22 (2.6) 0.2549
Crusts 10 (0.7) 2 (0.4) 8 (0.9) 0.3419
Lacrimation and conjunctiva 
hyperaemia
13 (1) 3 (0.6) 10 (1.2) 0.3950
Cacosmia 2 (0.1) 0 (0) 2 (0.2) 0.5358
Symptoms suggesting 
a complication*
Total 15 (1.1) 2 (0.4) 13 (1.5) 0.0603†
Orbital symptoms 
  Total 9 (0.7) 1 (0.2) 8 (0.9) 0.1673‡
  Palpebral oedema 6 (0.4) 1 (0.2) 5 (0.6) 0.4246
  Exophthalmos 0 (0) 0 (0) 0 (0) _
  Diplopia 1 (0.1) 0 (0) 1 (0.1) 1.0000
  Ocular pain 5 (0.4) 0 (0) 5 (0.6) 0.1652
  Decrease of visual acuity 2 (0.1) 0 (0) 2 (0.2) 0.5358
  Other orbital symptoms 2 (0.1) 0 (0) 2 (0.2) 0.5358
Frontal symptoms 
  Total 9 (1.1) 1 (0.2) 8 (0.9) 0.1673‡
  Intense frontal pain 9 (0.7) 1 (0.2) 8 (0.9) 0.1673
  Frontal oedema 1 (0.1) 0 (0) 1 (0.1) 1.0000
Neurological symptoms 0 (0) 0 (0) 0 (0) _
Systemic symptoms 0 (0) 0 (0) 0 (0) _
*Number of cases and proportion within group (%).
†χ2 test.
‡Fisher’s exact test
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similar in patients receiving antibiotic treatment or not. In 
the Netherlands, Hansen et al10 reported a very low rate of 
ARS complications in both children (1:12 000) and adult 
(1:32 000) patients, which suggested antibiotic treatment 
did not prevent complications. In our study, the frequency 
of symptoms suggesting complications was totally indepen-
dent of the prescribed medication.
Although the efficacy of INS in ARS remains controver-
sial, current guidelines1 and systematic reviews18 47 recom-
mend the use of INS in moderate (monotherapy) and 
severe (in combination with antibiotics) ARS. Dolor et al17 
first described that the addition of INS (fluticasone propio-
nate) to antibiotic treatment improved clinical success rates 
and accelerated recovery. Further studies demonstrated the 
superiority of INS (mometasone furoate) in monotherapy 
over placebo and even over amoxicillin to improve nasal 
symptoms48 49 and QoL37 in patients with moderate non-com-
plicated ARS. However these benefits are only clear when 
INS is used in high doses and during almost 3 weeks.18 48 
In common cold however INS is not related to better cure 
rates or symptom relief.50 In our study, Spanish physicians 
prescribe INS in two out of five (38%) patients with common 
cold and in one out of two (54%) patients with postviral 
ARS, with INS prescription being associated with a longer 
duration of the disease. As long as the present study is a real-
life study, a cause–effect relationship cannot be stated (see 
the limitations of the study at the end of this section), since 
physicians may reserve INS treatment for cases with more 
prolonged disease. Some studies have described the efficacy 
of herbal medicines such as Myrtol,51 Pelargonium sidoides,52 
and recently BNO 1016.53 In 2012, Pfaar et al54 reported that 
CE added on to antibiotics reached a better symptom control 
Table 5 Risk factors for a viral rhinosinusitis leading to a postviral acute rhinosinusitis (ARS)
Viral ARS
(n=237)
Postviral ARS
(n=452)
Total ARS
(n=689) OR 95% CI P
Age* 42.3±14.3 (237) 42.2±13.7 (452) 42.3±13.9 (689) 1.00 0.99 to 1.01 0.9104
Gender† 
  Men 111 (47) 208 (46) 319 (46) 1 0.8380
  Women 126 (53) 244 (54) 370 (54) 1.03 0.75 to 1.42
  Total 237 (100) 452 (100) 689 (100)
Area of  residence†
  Rural 12 (5) 20 (4) 32 (5) 1 0.5672
  Semirural 26 (11) 62 (14) 88 (13) 1.43 0.61 to 3.35
  Urban 199 (84) 370 (82) 569 (83) 1.12 0.53 to 2.33
  Total 237 (100) 452 (100) 689 (100)
Place of residence† 
  With family/couple 210 (89) 399 (88) 609 (88) 1
  Alone 23 (10) 48 (11) 71 (10) 1.10 0.65 to 1.86 0.9064
  Institution/residence 1 (0) 1 (0) 2 (0) 0.53 0.03 to 8.46
  Shared housing 3 (1) 4 (1) 7 (1%) 0.70 0.16 to 3.16
  Total 237 (100) 452 (100) 689 (100)
Education level† 
  No/unfinished education 13 (5) 30 (7) 43 (6) 1 0.4829
  Primary/secondary education 106 (4) 218 (48) 324 (47) 0.89 0.45 to 1.78
  College/higher education 118 (50) 204 (45) 322 (47) 0.75 0.38 to 1.49
  Total 237 (100) 452 (100) 689 (100)
Daily activity† 
  Well air-conditioned enclosure 171 (72) 302 (67) 473 (69) 1 0.0323
  Bad air-conditioned enclosure 16 (7) 64 (14) 80 (12) 2.26 1.27 to 4.04
  Outdoors 17 (7) 23 (5) 40 (6) 0.77 0.40 to 1.47
  Unemployed 33 (14) 63 (14) 96 (14) 1.08 0.68 to 1.71
  Total 237 (100) 452 (100) 689 (100)
Well-heated home† 221/237 (93) 407/452 (90) 628/689 (91) 0.65 0.36 to 1.19 0.1620
Airy home† 229/237 (97) 440/452 (97) 669/689 (97) 1.28 0.52 to 3.18 0.5933
*Arithmetic mean±SD (n).
†Number of cases and proportion within group (%).
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of ARS compared with placebo. In consequence, the EPOS 
guidelines recommended their use in adult ARS.1 A recent 
meta-analysis by Kock et al24 has confirmed the efficacy of 
some herbal compounds such as EPs 7630, Myrtol, BNO 
101, BNO 1016, CE and Esberitox. In the present study, an 
association was found between the use of CE and a shorter 
disease duration, suggesting CE be accepted by physicians as 
a treatment choice for ARS. In 2011 Wang et al27 published 
a study reporting a huge amount of medications prescribed 
in Asia to treat mild ARS (common cold). Over 80% of 
the general practitioners and ear, nose and throat (ENT) 
specialists prescribed at least one medication in ARS, with 
antihistamines (39.2%) and nasal decongestants (33.6%) 
being among the medications most frequently prescribed. 
Despite the fact that antihistamines and mucolytics have 
not shown any benefit on treating ARS, and are not recom-
mended by international guidelines,1 physicians, and espe-
cially PCPs but also ENT specialists, in our study regularly 
prescribed antihistamines (26%) and mucolytics (45%) to 
patients with ARS.
In summary, the management of mild to moderate ARS 
is quite similar as for severe/bacterial ARS (apart from 
the need of antibiotics in specific cases) as disease can be 
expected to resolve even when moderate or severe symp-
toms are present. The use of INS appears to help resolu-
tion of the disease.
Weaknesses and strengths
As with all epidemiological studies, the PROSINUS survey 
may have some weaknesses and limitations. (1) The 
study population cannot be considered a random sample 
since there was no control over which patients received 
specific medications, or in which patients diagnostic tools 
were performed. We have attempted to address this by 
estimating regression models adjusted for the ARS type 
and severity level at visit 1. In addition, the results have 
been interpreted in terms of association, avoiding any 
interpretation in terms of causality. (2) The management 
performed by PCPs (retrospective) and ORLs (prospec-
tive) cannot directly be compared since they were not 
parallel but consecutive groups with the same patients but 
assessed at different times. In addition, some unmet needs 
were identified in the study: clear validated criteria to 
define bacterial ARS and physicians’ criteria to prescribing 
antibiotics.
On the other hand the following are the strengths of the 
study: (1) the high number of included patients, and that 
EPOS criteria were followed for inclusion criteria and to clas-
sify our patients’ population; and (2) this is a real-life and 
prospective study providing physicians’ real approach to the 
management of the disease in their daily clinical practice.
Although this study is based on data collected in 2007, 
ARS has not suffered significant changes in either avail-
able diagnostic tools or therapeutic options since then in 
Spain. In addition, overuse of antibiotics remains a signif-
icant burden for many diseases in our society. In conse-
quence, we consider these findings very relevant for the 
current clinical practice.
COnClusIOns
To summarise our findings, despite the fact that consensus 
guidelines on ARS management have existed for more 
than a decade, a lot of diagnostic tools are still performed 
unnecessarily, and a lot of non-recommended medications 
are prescribed to treat a disease that is mostly self-limited. 
There is an important unmet need to educate physicians as 
much as policymakers to manage ARS following evidence-
based clinical practice guideline recommendations. It 
has been proven that education is effective in reducing 
antibiotic prescriptions for respiratory tract infections55 
and ARS.56 We found an overuse of diagnostic tools and 
prescribed medications but, in addition to the burden and 
mortality induced by antibiotic resistance due to antibiotic 
overuse, the associated direct and indirect costs remain to 
be analysed.
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